Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor
Gregorio D. Chazenbalk, … , Sandra M. McLachlan, Basil Rapoport
Gregorio D. Chazenbalk, … , Sandra M. McLachlan, Basil Rapoport
Published July 15, 2002
Citation Information: J Clin Invest. 2002;110(2):209-217. https://doi.org/10.1172/JCI15745.
View: Text | PDF
Article Aging

Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor

  • Text
  • PDF
Abstract

Research Article

Authors

Gregorio D. Chazenbalk, Pavel Pichurin, Chun-Rong Chen, Francesco Latrofa, Alan P. Johnstone, Sandra M. McLachlan, Basil Rapoport

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Neutralization by purified TSHR A subunits of TSHR autoantibodies from G...
Neutralization by purified TSHR A subunits of TSHR autoantibodies from Graves patients with hyperthyroidism. Flow cytometry was performed using sera from five Graves patients whose signal upon flow cytometry gave the largest differential between recognition of the wild-type TSHR and GPI-anchored ectodomain (Figure 4a). Sera were preincubated in either buffer alone or in buffer containing a large excess of TSHR-289 (0.1 μg/0.1 ml of serum diluted 1:50) before addition to CHO cells expressing ECD-GPI. TSHR-289 is a secreted, soluble, heavily glycosylated protein that comprises amino acid residues 22–289 of the TSHR, essentially the A subunit (residues 1–21 being the signal peptide). Net fluorescence values for the sera are indicated after subtraction of background fluorescence obtained with untransfected CHO cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts